An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFV)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line

British Journal of Cancer

Volumn 80, Issue 8, 1999, Pages 1214-1222

  Klimka, A ^a,b   Barth, S ^a   Matthey, B ^a   Roovers, R C ^b   Lemke, H ^c   Hansen, H ^c   Arends, J W ^b   Diehl, V ^a   Hoogenboom, H R ^b   Engert, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Kiel and Lungen Clinic Grosshansdorf   (Germany)

Author keywords

CD30; Hodgkin's lymphoma; Ki 4; Phage display; Recombinant immunotoxin

Indexed keywords

CD30 ANTIGEN; HYBRID PROTEIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PSEUDOMONAS EXOTOXIN; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; GENE AMPLIFICATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REED STERNBERG CELL;

EID: 0032987246     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690488     Document Type: Article

References (30)

1. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF, Bookman MA, Fand I, Houston LL and Weiner LM (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53: 4026-4034
2. Barth S, Huhn M, Wels W, Diehl V and Engert A (1998) Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Int J Mol Med 1: 249-256
3. Bradbury A, Ruberti F, Werge T, Amati V, Di Luzio A, Gonfloni S, Hoogenboom HR, Piccioli P, Biocca S and Cattaneo A (1995) The cloning of hybridoma V regions for their ectopic expression in intracellular and intercellular immunization. In Antibody Engineering, 2nd edn, Borrebaeck C (ed), p. 295. Oxford University Press: New York
4. Dower WJ, Miller JF and Ragsdale CW (1988) High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res 16: 6127-6145
5. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B and Stein H (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68: 421-427
6. Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V and Thorpe P (1990) Evaluation of ricin A-chain containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin's disease. Cancer Res 50: 84-88
7. Engert A, Gottstein C, Bohlen H, Winkler U, Schön G, Manske O, Schnell R, Diehl V and Thorpe P (1995) Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior antitumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int J Cancer 63: 304-309
8. Engert A, Diehl V, Schnell R, Radzuhn A, Hatwig MT, Drillich S, Schön G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J and Vitetta ES (1997) A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89: 403-410
9. Ghetie MA, Tucker K, Richardson J, Uhr JW and Vitetta ES (1992) The anti-tumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 80: 2315-2320
10. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blättler WA, Epstein CL and Nadler LM (1993) Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone-marrow transplantation for patients with B-cell non Hodgkin's lymphoma. Blood 81: 2263-2271
11. Gruss HJ and Dower SK (1995) The TNF ligand superfamily and its relevance for human disease. Cytokines Molec Ther 1: 75-105
12. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P and Winter G (1991) Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 19: 4133-4137
13. Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM and Lemke H (1995) Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-spccific antibody (Ki-4). Int J Cancer 60: 539-544
14. Klimka A, Barth S, Drillich S, Wels W, van Snick J, Renauld JC, Tesch H, Bohlen H, Diehl V and Engert A (1996) A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines. Cytokines Mol Ther 2: 139-146
15. Kreitman RJ and Pastan I (1994) Recombinant toxins. Adv Pharmacol 28: 193-219
16. Lorimer IAJ, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD and Pastan I (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeted with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93: 14815-14820
17. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD and Winter G (1991) Bypassing immunization: human antibodies from V-gene libraries displayed on phage. J Mol Biol 222: 581-597
18. Matthey B, Engert A, Klimka A, Diehl V and Barth S (1999) A new scries of pET-derived vectors for high efficiency expression of Pseudomonas Exotoxin-based fusion proteins. Genes (submitted)
19. McCafferty J, Fitzgerald KJ, Earnshaw J, Chiswell DJ, Link J, Smith R and Kenten J (1994) Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display. Appl Biochem Biotechnol 47: 157-171
20. Munro S and Pelham HR (1986) An Hsp70-like protein in the ER: identity with the 78 kD glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell 46: 291-300
21. Pasqualucci L, Flenghi L, Terenzi A, Bolognesi A, Stirpe F, Bigerna B and Falini B (1995) Immunotoxin therapy of hematological malignancies. Haematologica 80: 546-556
22. Plaksin D, Chacko S, McPhie P, Bax A, Padlan EA and Margulies DH (1996) A T cell receptor Vα domain expressed in bacteria: does it dimerize in solution? J Exp Med 184: 1251-1258
23. Roovers RC, Henderikx P, Helfrich W, van der Linden E, Reurs A, de Bruine A, Arends J-W, de Leij L and Hoogenboom HR (1998) High affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Br J Cancer 78: 1407-1416
24. Sahin C, Hartman F, Senter P, Pohl C, Engert A, Diehl V and Pfreundschuh M (1990) Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res 50: 6944-6948
25. Schnell R, Linnartz C, Katouzi AA, Schön G, Bohlen H, Horn-Lohrens O, Parwaresch RM, Lange H, Diehl V, Lemke H and Engert (1995) A development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer 63: 238-244
26. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M and Diehl V (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299: 65-67
27. Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, Kadin M, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F and Falini B (1996) Anti-CD30 (BerH2) immunotoxins containing the type-I ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful anti-tumor activity against CD30+ tumour cells in vitro and in SCID mice. Brit J Haematol 92: 872-879
28. Vitetta E, Thorpe PE and Uhr JW (1993) Immunotoxins: magic bullets or misguided missiles? Immunol Today 14: 252-259
29. Wels W, Harwerth IM, Müller M, Groner B and Hynes NE (1992) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52: 6310-6317
30. Wiley SR, Goodwin RG and Smith CA (1996) Reverse signaling via CD30 ligand. J Immunol 157: 3635-3639